Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers
Authors:
- Bothamai DechatesBDBothamai Dechates
- Thachanun PorntharukchareonTPThachanun Porntharukchareon
- Supamas SirisreetreeruxSSSupamas Sirisreetreerux
- Phonthip TherawitPTPhonthip Therawit
- Supanat WorawitchawongSWSupanat Worawitchawong
- Gaidganok SornsamdangGSGaidganok Sornsamdang
- Kamonwan SoonklangKSKamonwan Soonklang
- Kriangkrai TawinpraiKTKriangkrai Tawinprai
Open Access
Abstract
Background: Vaccines for SARS-CoV-2 have been critical for preventing disease. Previous research showed patients with diabetes have impaired immunity. This study aimed to determine the immunity to coronavirus after CoronaVac by comparing patients with type 2 diabetes (T2D) and healthcare workers (HCW). Materials and methods: A prospective cohort study evaluated immune responses and safety after two doses of CoronaVac in T2D and HCW groups at Chulabhorn Hospital. The levels of total antibodies against the receptor-binding domain (anti-RBD) of the SARS-CoV-2 spike protein at baseline and 4 weeks after vaccination were collected. The level of anti-RBD concentrations was reported as geometric mean concentration (GMC) and compared between groups using the geometric mean ratio (GMR). Results: 81 participants were included; 27 had T2D and 54 were HCW. After complete vaccination, anti-RBD concentrations were not significantly different between T2D (57.68 binding antibody units (BAU)/mL, 95% confidence interval (CI) = 29.08; 114.44) and HCW (72.49 BAU/mL, 95% CI = 55.77; 94.22) groups. Subgroup analysis showed the GMC of anti-RBD was significantly lower in T2D patients with dyslipidaemia (50.04 BAU/mL) than in T2D patients without dyslipidaemia (341.64 BAU/mL). Conclusions: The immune response at 4 weeks after two doses of CoronaVac did not significantly differ between patients with T2D and HCW.Keywords
Funding Information
- Chulabhorn Royal Academy
This publication has 36 references indexed in Scilit:
- Infections in Patients with Diabetes MellitusNew England Journal of Medicine, 1999
- Immune dysfunction in patients with diabetes mellitus (DM)FEMS Immunology & Medical Microbiology, 1999
- Insulin Infusion Improves Neutrophil Function in Diabetic Cardiac Surgery PatientsAnesthesia & Analgesia, 1999
- Immunologic Effects of Acute Hyperglycemia in Nondiabetic RatsJournal of Parenteral and Enteral Nutrition, 1997
- Polymorphonuclear Leukocytes in Non-Insulin-dependent Diabetes Mellitus: Abnormalities in Metabolism and FunctionAnnals of Internal Medicine, 1995
- Changes in phagocytic function with glycaemic control in diabetic patients.Journal of Clinical Pathology, 1989
- Defective phagocytosis in insulin controlled diabetics: evidence for a reaction between glucose and opsonising proteins.Journal of Clinical Pathology, 1984
- Infection and Diabetes MellitusDiabetes Care, 1980
- Impaired Granulocyte Adherence: A Reversible Defect in Host Defense in Patients with Poorly Controlled DiabetesDiabetes, 1978
- Influence of Intermittent Hyperglycemic Glucose Levels on the Phagocytosis of Microorganisms by Human Granulocytes in VitroImmunological Communications, 1978